A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors.

Trial Profile

A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Dabrafenib (Primary) ; Antineoplastics; Trametinib
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 26 Sep 2017 Planned End Date changed from 31 Oct 2017 to 30 Nov 2017.
    • 26 Sep 2017 Planned primary completion date changed from 31 Oct 2017 to 30 Nov 2017.
    • 14 Sep 2017 Planned End Date changed from 15 Dec 2017 to 31 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top